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Abstract 
Papillomaviruses have evolved mechanisms that result in escape from host immune 
surveillance. The E5 protein is expressed early in papillomavirus infection in the deep layers 
of the infected epithelium. It is localised to the Golgi apparatus (GA) and endoplasmic 
reticulum. The E5 protein of bovine papillomavirus (BPV) impairs the synthesis and stability 
of major histocompatibility (MHC) class I complexes and prevents their transport to the cell 
surface due to retention in the GA. Here we show that human papillomavirus type 16 (HPV-
16) E5 also causes the retention of MHC (HLA) class I complexes in the GA and impedes 
their transport to the cell surface, which is rescued by treatment with interferon. Unlike BPV 
E5, HPV-16 E5 does not affect the synthesis of HLA class I heavy chains, nor the expression 
of the transporter associated with antigen processing TAP.  These results show that down-
regulation of surface MHC class I molecules is common to both BPV and HPV E5 proteins.  
Moreover, we determined that HPV-16 E5 down-regulates surface expression of HLA-A and 
HLA-B, which present viral peptides to MHC class I-restricted cytotoxic T lymphocytes 
(CTL), but not the natural killer (NK) cell inhibitory ligands HLA-C and HLA-E.  Selective 
down-regulation of cell surface HLA class I molecules may allow the virus to establish 
infection by avoiding immune clearance of virus-infected cells by both CTL and NK cells. 
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 Introduction 
Papillomaviruses (PV) are small DNA tumour viruses which infect the epithelia of 
humans and animals causing benign hyperproliferative lesions. In most cases PV infections 
are cleared after several months following activation of the host immune system against viral 
antigen 1. However, occasionally the lesions do not regress and can progress to cancer. 
Certain PV are more commonly associated with malignancy, including the human PV (HPV) 
types 16 and 18, “high risk” viruses for the development of cervical cancer in women 2, and 
bovine PV (BPV) type 4, associated with carcinomas of the alimentary canal in cattle 3. 
Persistent viral infection is required for neoplastic progression and failure of virus clearance 
is attributed to a poor immunological response.  
The PV genome encodes three transforming proteins, E5, E6 and E7. E5 is a small 
hydrophobic protein ranging in size from 42 amino acid residues in BPV-4 to 83 amino acid 
residues in HPV-16. E6 and E7 are the main transforming proteins of HPV 4, 5; E5 is the 
major transforming protein of BPV and plays a lesser role in transformation by HPV 6. While 
E6 and E7 are expressed throughout the course of the disease and are necessary for the 
maintenance of a transformed phenotype, E5 is expressed only during the early stages of 
infection and its expression is often, but not always, extinguished as the lesion progresses 
toward malignancy 6. These characteristics point to a role of E5 in establishment of PV 
infection and the initiation of cell transformation.  
The E5 protein is localized in the Golgi apparatus (GA), endoplasmic reticulum and 
occasionally the plasma membrane of the host cell. Its localisation in the endomembrane 
compartments, where it interacts with the vacuolar ATPase 16k ductin/subunit c 7-9, is 
deemed responsible for the lack of acidification of the GA and endo-lysosomes and the 
consequent impaired functions of these organelles 10, 11.  
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We have shown that one of the outcomes of BPV E5 expression in primary cells is the 
retention of major histocompatibility (MHC) class I complexes in the GA and the inhibition 
of their transport to the cell surface 12, 13. Furthermore, BPV E5 inhibits both transcription of 
the MHC class I heavy chain gene and affects the stability of the heavy chain protein 12. In 
this study we show that HPV-16 E5 also prevents the transport of MHC (HLA) class I 
complexes to the cell surface due to retention in the GA.  Moreover, we show that HPV-16 
E5 selectively down-regulates HLA-A and HLA-B molecules on the cell surface but does not 
affect the transport of HLA-C and HLA-E. These studies identify a potential novel 
mechanism by which PV-infected cells may avoid clearance by cytotoxic T lymphocytes 
(CTL) and natural killer (NK) cells, aiding in the establishment and persistence of PV 
infection. 
 
Deleted: epithelial 
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Materials and Methods 
HPV-16 E5 expression constructs.  
The E5 ORF was cloned into three expression plasmids: pcDNA3 (Invitrogen, 
Glasgow, UK), under the transcriptional control of the universal cytomegalovirus (CMV)  
immediate early promoter  (pc-16E5); pL2, under control of the Epstein-Barr virus (EBV) 
ED-L2 promoter, active only in epithelial cells 14 (pL2-16E5), and the retrovirus expression 
plasmid pLZRSpBMLZ (Clontech, UK). Amphotropic retrovirus expressing HPV-16 E5 
(RT-16E5) was generated by transient transfection of the packaging cell line Phoenix 15 as 
previously described 12. 
Establishment of HPV E5-expressing cell lines  
The immortalised human keratinocyte HaCaT cell line was grown in Dulbecco’s 
Modified Eagle Medium (DMEM) without CaCl2 (Invitrogen), supplemented with 1mM 
sodium pyruvate, 2mM glutamine and 10% fetal calf serum (FCS) at 37°C in 5% CO2. 
Primary bovine PalF cells 12 and NIH 3T3 cell lines were grown in DMEM, 10% FCS at 
37oC in 5% CO2. 
 HaCaT cells were stably transfected with 4 μg of pcDNA, pL2, pc-16E5 or pL2-
16E5 per 1x106 cells using Lipofectamine Plus (Invitrogen) according to the manufacturer’s 
instructions. Following transfection, the cells were selected in DMEM containing 500μg/ml 
G418 (Invitrogen) for 21 days. After this time, G418-resistant colonies were marked, 
individually picked and expanded into clonal cell lines  for analysis.  
The retrovirus RT-16E5, or its empty counterpart (generated using wild-type 
pLZRSpBMLZ plasmid), was used to infect primary PalF cells as described 12 and the cells 
were analysed two days later. 
NIH3T3 cells expressing HPV-6b E5 or HPV-16 E5 under the control of the mouse 
moloney leukaemia virus (MMLV) LTR in pZip-neo, were a kind gift from Dr Show-Li  
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Chen (National Defence Medical Center, Taipei, Taiwan) and Prof Richard Schlegel 
(Georgetown University, Washington, USA), respectively.   
Quantitative RT-PCR 
Total RNA was isolated from HaCaT cells using the RNeasy Mini kit (Qiagen, 
Crawley, UK), and residual DNA was removed by DNase I treatment (Invitrogen).  Real-time 
RT-PCR for HPV-16 E5 and β-actin mRNA was carried out using the Taqman EZ RT-PCR 
kit (Applied Biosystems, USA). Each reaction was performed in triplicate using 100 ng of 
RNA. Oligonucleotide primers, designed using Primer Express (v1.7, Perkin-Elmer, UK) 
were as follows: 16E5wt F 5’-TGACAAATCTTGATACTGCATCCA-3’; 16E5wt R 5’-
CTGCTGTTATCCACAATAGTAATACCAATA-3’; and a FAM/TAMRA probe 5’-
AACATTACTGGCGTGCTTTTTGCTTTGCT-3’. Primers and probe sequences for β-actin 
quantitation were purchased from Applied Biosystems (UK). PCR reactions were performed 
using an ABI Prism 7700 Sequencer.  Standard curves were generated using 10-fold serial 
dilutions of each template DNA, which were used to quantitate the relative levels of E5 and 
β-actin mRNA.  E5 mRNA levels were normalized according to the β-actin controls.   
FACS analysis of MHC class I expression 
HaCaT, PalF and NIH3T3 cells were grown in T175 cm2 flasks until sub-confluent. 
After removal of the medium, the cells were washed once with PBS, then detached from the 
flask with trypsin/EDTA and pelleted at 200g for 5 min at room temperature (RT). The cell 
pellet was resuspended in DMEM, 10% FCS and incubated for 1 hour at 37°C to allow 
surface antigens to be re-expressed. The cells were then washed and resuspended in PBS/1% 
bovine serum albumin (BSA) (PBS-B) at a concentration of 107 cells/ml. For the detection of 
surface MHC class I molecules, 100μl of cells were aliquoted and incubated for 1 hour at 4C 
with an equal volume of monoclonal antibody (mAb) as follows: pan anti-human MHC class 
I W6/32 (1:100; Serotec, UK), anti-bovine MHC class I IL-A19 (1:1000) 16, anti-mouse H-
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2Ld CL9011-A (1:50; Cedarlane Laboratories, UK), or anti-HLA-C/E DT9 (1:50; a kind gift 
from Dr Veronique Braud, Centre National de la Recherche Scientifique, Sophia Antipolis, 
France) for 30 min at 4°C. Following three washes in PBS-B cells were incubated with 1:100 
dilution of anti-mouse IgG-FITC (Sigma, UK) for 30 min at 4°C in the dark. The cells were 
then washed as above, resuspended in 500μl PBS-B and analysed by flow cytometry. If the 
flow cytometry analysis was not performed immediately, the cells were resuspended in 500μl 
of 3% paraformaldehyde in PBS and kept at 4°C. A mouse monoclonal antibody against 
HPV-16 E2 (TVG261; a kind gift of Dr M. Hibma) was used as negative control (1:50).  
For the detection of intracellular MHC class I, the cells were first permeabilised with 
0.5% saponin in PBS-B for 30 min at RT. Following a wash in PBS-B, the cells were then 
incubated with primary antibody as described above.  
All samples were examined in a Beckman Coulter EPICS Elite analyser equipped 
with an ion argon laser with 15 mV of excitation at 488 nm. The data were analysed using 
Expo 2 software.  
Immunofluorescence detection of MHC class I and GA.  
In all experiments, HaCaT cells (1x104) were aliquoted into 24-well plates containing 
coverslips and grown overnight. After removal of the medium, cells were washed twice with 
PBS and fixed in 1.85% formaldhehyde in PBS containing 2% sucrose for 10 min at RT. 
After fixation, cells were washed twice and incubated in permeabilising solution (0.5% NP-
40, 10% sucrose in PBS) for 10 min at RT and then washed as above. 
For detection of MHC class I, the fixed and permeabilised cells were incubated with 
1:50 dilution of W6/32 antibody for 1 hour at RT.   Following a further two washes, the cells 
were incubated with 1:500 dilution of anti-mouse IgG-FITC (Sigma) for 1 hour at 4°C in the 
dark. For visualisation of the GA, the cells were incubated with mAb 4A3 (1:200) 
recognising golgin GM130, an integral GA protein 17 for 1 hour at RT. Following two washes 
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as above, the cells were incubated with 1:1000 dilution of anti-mouse IgG-TRITC (Sigma) 
for 1 hour at 4°C in the dark.  
To analyse the localization of MHC class I in E5-expressing cells, control HaCaT 
cells (pcDNA and pL2) and E5-expressing cells (pc-16E5 and pL2-16E5) were incubated 
with mAb 4A3, washed as described above then incubated with anti-mouse IgG-TRITC 
(1:1000), and FITC-conjugated W6/32 (1:10; Sigma).  
In all cases, the cells were washed three times after incubation with secondary 
antibody, and the coverslips mounted onto slides using CitifluorTM.  Images were captured 
using a Leica TCS SP2 true confocal scanner microscope (Leica-microsystems, Heidelberg 
Germany) and a wavelength of 488nm (MHC class I) or 543nm (GA).  The merge between 
the FITC and TRITC fluorescent signals was achieved using the Leica TCS SP2 
accompanying software.   
Immunoblotting detection of MHC class I and TAP.  
HaCaT cells were removed from the flasks by trypsinisation, washed with PBS, then 
lysed by sonication in lysis buffer (100mM Tris HCl, pH 7.5, 2% SDS, 20% glycerol) and 
insoluble material removed by centrifugation at 20,000g for 10 min at 4C. Ten µg of lysate 
were electrophoresed in 4-12% NuPAGE gels (Invitrogen), and proteins transferred to 
nitrocellulose membrane using a semidry blotting apparatus at 20V/150A for 1 hour. The 
membranes were blocked in 5% milk in Tris-buffered saline (TBS) containing 0.05% Tween 
20 (TBST) for 1 hour at RT. 
For detection of MHC class I, the membranes were incubated with the following 
mAb: HC10, specific for HLA class I heavy chain (1:50; a kind gift from Dr Stephen Man, 
Cardiff University), MEM-E/02 specific for human HLA-E (1:50; Serotec), or AB-1 
(1:20,000; Oncogene Research Products, UK) specific for actin. For detection of the 
transporter associated with antigen processing TAP, the membranes were incubated in 1:1000 
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dilution of rabbit anti-TAP-1 antibody (Chemicon, UK). After repeated washing with TBST 
the membranes were incubated with either 1:20,000 dilution of anti-mouse Ig-HRP 
(Amersham Pharmacia Biotech, UK) for HC10 and MEM-E/02, 1:5000 dilution of anti-
mouse IgM-HRP (Oncogene Calbiochem-Novabiochem International, UK) for AB-1, or 
1:5000 dilution anti-rabbit IgG-HRP (Sigma), in 5% milk/TBST for 1 hour at RT. The 
membranes were washed three times with TBST and bound antibody detected by enhanced 
chemoluminescence (ECL) (Amersham Pharmacia Biotech). 
Treatment of cells with interferon  
One million parental HaCaT cells, control cells expressing pcDNA3 or pL2, and cells 
expressing HPV-16 E5 were seeded in T175 cm2 tissue culture flasks. The following day, the 
medium was replaced with fresh medium with or without 500 U/ml β-IFN (Sigma). After 48 
hours, the cells were harvested for detection of MHC class I by immunofluorescence or flow 
cytometry analysis as described above. 
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Results 
Detection of E5 expression in cell lines 
As E5 is expressed at very low levels in cells and there are no reliable antibodies 
against the protein, it is very difficult to detect its expression by immunoblotting 18. Therefore 
we instead confirmed that the E5 ORF was being transcribed using quantitative RT-PCR.  
Ten clones from each HaCaT cell transfection with pcDNA, pL2, pc-16E5 or pL2-16E5 were 
picked and expanded into cell lines for analysis.  RNA was isolated and the relative level of 
E5 mRNA expression was determined by comparison to β-actin mRNA. The results of 6 
clones expressing HPV-16 E5 (3 as pc-16E5 and 3 as pL2-16E5) are shown in Figure 1. 
Although low (four orders of magnitude less than that of β-actin), all of the cell lines 
expressed E5 mRNA. The amount of E5 mRNA was comparable among each cell line, 
ranging from approximately 0.01-0.02 pg per 100ng of RNA. The levels of E5 mRNA in 
HaCaT keratinocytes are approximately one hundred-fold lower than those in W12 cells 
(derived from cervical intraepithelial neoplasia) 19, which express E5 from the resident multi-
copy episomal HPV-16 genome (data not shown). This observation therefore excludes the 
possibility that any effect seen in HaCaT cells is due to E5 over-expression.   
Down-regulation of surface HLA class I in cells expressing HPV E5 
Given that BPV E5 can inhibit transport of MHC class I molecules to the cell surface 
12, 13 we investigated whether HPV-16 E5 could likewise down-regulate surface HLA class I. 
Using FACS analysis, we determined the levels of HLA class I in HaCaT cell lines 
expressing HPV-16 E5 under the control of the CMV promoter (pc-16E5) or expressing E5 
under the control of the epithelial-specific EBV promoter (pL2-16E5). HaCaT cells 
harbouring empty plasmids expressed similar levels of HLA class I as parental HaCaT cells, 
with approximately twice as much total (surface plus intracellular) HLA class I than surface 
alone (Figure 2A). In contrast, all of the pc-16E5 and pL2-16E5 HaCaT cell lines analysed 
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had reduced levels of surface HLA class I, approximately half that of the control or parental 
cells, whereas the level of total HLA class I remained constant (Figure 2A). This effect was 
highly reproducible, and specific as no signal above background (secondary antibody only) 
was detected when an anti HPV-16 E2 antibody was used (Figure 2C). Furthermore, we 
showed a marked reduction of surface MHC class I in NIH 3T3 mouse fibroblasts expressing 
HPV-6 E5 or HPV-16 E5 under the MMLV LTR, and in primary bovine PalF cells acutely 
infected with recombinant retrovirus expressing HPV-16 E5 (RV-16E5) (Figure 2B). These 
results show that down-regulation of MHC class I is stimulated by E5 proteins encoded by 
both BPV and HPV, including low risk (HPV-6) and high risk (HPV-16) viruses. Moreover, 
stimulation of MHC class I down-regulation in primary cells (PalF) shows that this effect is 
not due to the immortalised phenotype of the HaCaT keratinocytes.  
HLA class I is retained in the GA in E5-expressing epithelial cells   
To ascertain the intracellular localisation of HLA class I, E5-expressing HaCaT cell 
lines, parental and control cell lines, were co-stained with the antibodies W6/32 (pan MHC 
class I) and 4A3 (anti-golgin). In the control cells, HLA class I was expressed both on the cell 
surface and in the GA (Figure 3A). Identical staining patterns were observed in parental 
HaCaT cells (data not shown).  In contrast, in HPV-16 E5-expressing cells HLA class I was 
detected almost exclusively in the GA  (Figure 3B).  These results show that HPV-16 E5 
prevents the HLA class I complex from reaching the cell surface, and retains it in the GA .  
Expression of HLA class I heavy chain is not inhibited by HPV-16 E5  
The results above suggested that, in contrast to BPV E5, HPV-16 E5 did not have any 
effect on the overall levels of the HLA class I heavy chain. To confirm this observation, we 
determined the relative levels of HLA class I in the control and E5-expressing HaCaT cell 
lines using mAb HC10, specific for the human HLA class I heavy chain 20. Although the 
levels of HLA class I heavy chain were slightly lower in the pL2 and pL2-16E5 cell lines 
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than in the pcDNA and pc-16E5 cell lines, there were no significant differences between the 
cells expressing HPV-16 E5 and their respective control cells (Figure 4), confirming that 
HPV-16 E5 does not down-regulate expression of the HLA class I heavy chain.  
E5 has no effect on TAP expression.  
Transport of class I complexes to the cell surface is prevented if the transporter 
associated with antigen processing (TAP) is malfunctioning 21. Therefore it was important to 
establish whether E5 was affecting HLA class I transport by inhibiting TAP expression, as 
reported for HPV-11 E7 22. TAP-1 protein was investigated in control and E5-expressing 
HaCaT cell lines by immunoblotting. There appeared to be a lower level of TAP-1 in the pL2 
cells but there was no significant reduction of TAP-1 in cells expressing E5 (Figure 4), 
indicating that down-regulation of surface HLA class I is not due to an ability of E5 to down-
regulate TAP-1. An effect on the functionality of TAP cannot however be ruled out.  
Treatment of E5 cells with interferon rescues HLA class I traffic to the cell surface.  
β-interferon (β-IFN) increases transcription from the MHC class I heavy chain gene 
promoter 23 leading to higher expression of heavy chain. To determine if increased synthesis 
of heavy chain led to an increase in transport of HLA class I complexes to the cell surface, 
we treated HaCaT parental, control and E5-expressing cells with β-IFN, and analysed HLA 
class I expression and localisation by FACS and immunofluorescence. Treatment with β-IFN 
increased the total amount of HLA class I approximately two-fold in all of the cell lines 
tested (Figure 5A, cf. with Figure 2A). Moreover, we found an approximately two-fold 
increase in surface HLA class I in the parental and control cells, and an approximately four-
fold increase in the E5-expressing cells (Figure 5A, cf. with Figure 2A). This resulted in all 
of the cell lines, including those expressing HPV-16 E5, as having similar levels of surface 
HLA class I. β-IFN treatment did not affect expression of E5 (data not shown) and therefore 
the observed increase in HLA class I levels cannot be attributed to changes in E5 expression. 
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Unlike in BPV E5-expressing cells 13, β-IFN treatment therefore appeared to overcome the 
block exerted by E5 on HLA class I transport. To confirm this observation, HaCaT cells 
carrying empty vector or expressing HPV-16 E5, untreated or treated with IFN, were 
incubated with mAb W6/32 and analysed for HLA class I localisation. In the untreated E5-
expressing cells, HLA class I was mostly detected in the GA, as before (Figure 5B). In 
contrast, HLA class I was detected on the surface of E5-expressing cells treated with IFN. 
These experiments show that HPV-16 E5-expressing cells are responsive to IFN and that the 
E5-induced HLA class I transport inhibition is reversible by IFN.  
HLA-C/E expression is not inhibited by HPV-16 E5  
While MHC class I molecules HLA-A and -B are the main presenters of antigenic 
peptides to CTL, HLA-C and non-classical MHC molecules, such as HLA-E, inhibit NK cell-
mediated lysis by interacting with inhibitory NK receptors 24-26. To determine whether HPV-
16 E5 could selectively down-regulate HLA class I molecules, we determined the levels of 
HLA-C/E in parental, control and E5-expressing HaCaT cell lines. Cells were stained with 
mAb DT9 that recognises both HLA-C and -E, and were analysed by flow cytometry for 
surface and total HLA-C/E. Although the shift in forward fluorescence was small (Figure 
6A,B), in agreement with the observation that human fibroblasts have little HLA-E 27, it was 
consistently higher than background (secondary antibody only; Figure 6B), and higher than 
the readings obtained with an unrelated antibody (Figure 2C); Importantly, there were no 
significant differences between the control and E5-expressing cells (Figure 6A).  
In addition, we determined the cellular localisation of HLA-C/E in the E5-expressing 
cells by immunofluorescence using mAb DT9. There were no differences between the 
staining patterns of HLA-C/E in the control cells and in the E5-expressing cells (Figure 6C), 
and therefore we conclude that expression of E5 does not lead to any appreciable decrease in 
surface HLA-C/E, in agreement with the FACS data.  
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Finally, we determined the levels of total HLA-E by immunoblotting with mAb 
MEM-E/02, specific for HLA-E.  Similarly, we did not detect any significant differences 
between HLA-E levels in the control cells and the E5-expressing cells (Figure 6D).  
The ease of HLA-C/E detection by immunofluorescence and immunoblotting 
compared with flow cytometry is likely attributable to the different affinities of the two 
antibodies for HLA (mAb DT9 and MEM-E/02) and to the greater sensitivity of mAb DT9 in 
immunofluorescence.  
These results confirm that HPV-16 E5 down-regulates the surface expression of the 
classical HLA class I molecules HLA-A and -B, but not HLA-C or -E. We are unable to 
discriminate between HLA-C and HLA-E as mAb DT9 recognises both molecules, and mAb 
MEM-E/02, specific for HLA-E, does not function in flow cytometry or 
immunofluorescence.    
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Discussion 
 Progression from acute HPV infection to malignancy requires persistence of virus, 
which in turn appears to depend on several factors, including the genetic background of the 
host 28,29, environmental co-factors 30 and the ability of the virus to avoid immune clearance31. 
The immune system plays a decisive role in determining the clinical outcome of HPV 
disease, as demonstrated by the increased persistence and enhanced neoplastic progression of 
HPV infections in hosts with cell-mediated immune deficiencies 32,33. However, even in 
immunocompetent individuals, HPV persist for a significant period of time before activation 
of the host immune system. This lack of recognition suggests the host immune system is 
unaware of, or disabled by, HPV infection. HPV can subvert the immune response indirectly 
via the nature of the virus life cycle 34 and by direct interference with the host anti-viral 
immune mechanisms, including the IFN response and MHC class I antigen presentation to 
CTL 1, 35.  
MHC class I (HLA class I in humans) plays a pivotal role in the eradication of virally 
infected and transformed cells. The importance of MHC class I in virus clearance is 
highlighted by the acquisition of numerous mechanisms of interference with the MHC class I 
pathway by many viruses 36. Independently of the molecular nature of these mechanisms, the 
outcome is failure of the infected cells to effectively present viral peptides to effector CTL, 
resulting in avoidance of detection and destruction.  
We have recently shown that both BPV-4 and BPV-1 interfere with the MHC class I 
pathway, through the retention of MHC class I complexes in the GA by the oncoprotein E5 1, 
12, 13. Here we show that these properties are not a peculiarity of BPV E5 but are shared by E5 
proteins of mucosal HPV, including E5 encoded by the low risk HPV type 6, the etiological 
agent of genital warts, and HPV-16, the papillomavirus most frequently associated with 
cervical carcinoma. Since our initial observations were published, it has also been reported 
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that HPV2a E5 can inhibit HLA class I transport to the cell surface 37. Therefore, down-
regulation of surface MHC class I appears to be a property of many, if not all, papillomavirus 
E5 proteins.    
We found that HPV-16 E5 promotes the retention of HLA class I in the GA, a salient 
characteristic of cells expressing BPV-4 E5. It is established that E5 proteins bind 16k 
subunit c, a component of the V0 sector of the H+ V-ATPase 7-9 and that a possible outcome 
of this interaction is the inhibition of acidification of the GA and endosomes 10, 11. The 
retention of MHC class I in the GA by BPV-4 E5 is due, at least in part, to the impeded 
acidification of the organelle, as retention in the GA and down-regulation of surface MHC 
class I are also caused by monensin, an inhibitor of V-ATPase and GA acidification 13. The 
same mechanism may underpin the retention of HLA class I in the GA by HPV-16 E5. 
However, given the selective down-regulation of HLA types by HPV-16 E5, the lack of GA 
acidification cannot be the whole explanation and other mechanisms must come into play. 
These points are currently under investigation.    
Despite the similarities, there are also differences between the extent to which BPV-4 E5 
and HPV-16 E5 interfere with the MHC class I pathway. BPV-4 E5 down-regulates 
transcription of the MHC class I heavy chain gene, promotes degradation of the translated 
polypeptide and blocks the transport of the MHC class I complex to the cell surface 12, 13.  In 
contrast, HPV-16 E5 does not inhibit expression of the heavy chain, and reduces the transport 
of HLA class I to the cell surface without completely abolishing it. Furthermore, contrary to 
what we observed with BPV E5 13, inhibition of HLA class I transport by HPV-16 E5 is 
reversible by IFN treatment. The reason for this latter difference is not known but it can be 
speculated that the increased production of HLA class I heavy chain by IFN is sufficient to 
overcome the inhibitory effect mediated by the low levels of HPV-16 E5. In contrast, as BPV 
E5 also inhibits transcription and promotes degradation of the MHC class I heavy chain 12, 
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IFN treatment is insufficient to restore MHC class I expression to normal levels.  These data 
are also consistent with our hypothesis that there is a correlation between protein 
oncogenicity and immune evasion 38.  As discussed earlier, BPV E5 is a more effective 
transforming protein than HPV-16 E5 6 and therefore would be predicted to have a greater 
effect on MHC class I down-regulation (and other immune evasion mechanisms) than HPV-
16 E5.  In contrast, in oncogenic HPV infections, the two major transforming proteins E6 and 
E7 would complement the inhibitory effect of the lesser transforming protein E5 on the MHC 
class I pathway.  HPV-16 E7 can repress the MHC class I heavy chain gene promoter 39 thus 
likely replacing the inhibitory action of BPV on the same promoter, and in addition can bind 
directly to TAP, thus further contributing to the down-regulation of HLA class I 21. 
Furthermore, both HPV E6 and E7 can inhibit the type I IFN pathway, thus preventing the 
IFN-mediated release of E5-induced blockage in HLA class I trafficking 40-42.  
Although an efficient mechanism to avoid CTL-mediated immune clearance, the total 
absence of surface MHC class I renders cells more susceptible to NK cell attack. Human NK 
cells express multiple receptors that interact with HLA class I molecules, including killer cell 
immunoglobulin-like receptors (KIR) that predominantly recognise classical HLA class I 
including HLA-C, and the C type lectin superfamily of receptors that specifically interact 
with the non-classical class I molecule HLA-E 24-26.  Recognition of the class I molecules by 
their inhibitory receptors inhibits NK-mediated cell lysis, which would occur in the absence 
of HLA-C/E.  Accordingly, certain viral proteins, including HIV Nef and the US3/UL40 
proteins of CMV, have evolved to selectively down-regulate HLA-A and -B, the main 
presenters of peptides to CTL, but not HLA-C or –E  27,44,45, and are therefore capable of 
avoiding both CTL and NK cell killing 46. We show here for the first time that 
papillomaviruses, in particular HPV-16, may also employ a similar immune evasion strategy 
via expression of E5. Our experiments show that neither synthesis nor transport to the cell 
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surface of HLA-C/E is affected by E5 expression, leading to the conclusion that E5 
selectively inhibits surface expression of HLA-A and HLA-B. NK cells of patients with 
HPV-induced anogenital lesions are incapable of specific killing HPV-16-infected cells 47, 
although the mechanism by which this occurs is as yet unknown. Moreover, concordant with 
loss of MHC class I molecules that present viral peptides, there is a very low frequency of 
HPV-specific HLA-A-restricted CTL in patients infected with HPV-16, an order of 
magnitude lower than those found in other viral infections including influenza A and EBV  48. 
It is not yet known whether these observations are the consequence of E5 expression, 
however experiments to establish the functional outcome of E5 expression on CTL and NK 
cell recognition of HPV-transfected cells are in progress. 
Regardless, our results support the hypothesis that E5 plays a major role in immune 
evasion by HPV.  To this end, it is interesting to note that HPV-16 E5 has also been reported 
to inhibit both Fas ligand- and tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis in HaCaT cells 49, and, consistent with its role in the 
alkalinisation of endosomes, prevents the endosomal breakdown of the invariant chain 50, a 
chaperone important in the maturation of HLA class II, leading to inhibition of expression of 
surface  HLA class II 50. Therefore E5 can disrupt several critical components of the cell-
mediated immune response to viruses, which may contribute to the establishment and 
persistence of HPV infection. 
It remains to be seen if E5 expression causes HLA class I down-regulation also in vivo. 
This appears to be the case in bovine papillomas (our unpublished observations); HLA class I 
down-regulation has been observed in CIN 51 and in cervical carcinomas 52. However the 
down-regulation of HLA class I in cervical carcinomas, which often do not express E5, is 
common to other cancer types, and therefore unlikely to be due to E5. No correlation was 
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made between HLA class I down-regulation and E5 expression in CIN, and this point 
warrants further investigation.  
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Figure Legends 
 
Figure 1. Expression of E5 RNA in transfected cell lines. HaCaT cells were transfected with 
pcDNA3 (pcDNA), pcDNA3 expressing the HPV-16 E5 ORF (pc-16E5), pL2, or pL2 
expressing the E5 ORF (pL2-16E5). Quantitative RT-PCR was used to determine the relative 
amount of HPV-16 E5 and β-actin mRNA in three of each cell line.  The results of six 
representative cell lines are shown.  Relative RNA values are expressed as the mean of three 
independent experiments +/- standard deviation.    
Figure 2. HPV E5 down-regulates surface HLA class I. A, Parental HaCaT cells (three lines), 
cells harbouring empty vectors (pcDNA3, three lines; pL2, four lines), or expressing HPV-16 
E5 (pc-16E5, four lines; pL2-16E5, three lines) were analysed for expression of total and 
surface HLA class I by FACS with mAb W6/32. The average mean fluorescence for each 
expression vector was calculated from the flow cytometric analyses. A background of 0.4 
(the reading of cells stained with no primary antibody and only secondary antibody) was 
subtracted in all cases. Standard deviation (+/- ) is shown. B, FACS analysis of surface and 
total MHC class I in NIH 3T3 cells carrying empty vector (pZip), expressing HPV-6b E5 
(pZ-6E5), or HPV-16 E5 (pZ-16E5), and in PalF cells carrying empty retrovirus (empty RV), 
or expressing HPV-16 E5 (RV-16E5). One cell line of each was analysed. C, FACS analysis 
with an unrelated antibody (anti HPV-16 E2) showing no reaction above background. 
Figure 3. HLA class I is retained in the Golgi apparatus in HPV-16 E5-expressing cells. 
HaCaT cells carrying empty vectors or expressing E5 (at least three lines of each) were 
stained with mAb W6/32 (anti-HLA class I) and mAb 4A3 (anti-golgin GM130) and 
analysed using confocal microscopy. N, nucleus. Representative cells are shown. 
Figure 4. HPV-16 E5 does not inhibit expression of HLA heavy chain or TAP. Equal 
amounts (10μg) of protein lysates from one line each of HaCaT cells carrying empty vectors 
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(pcDNA, pL2) or expressing HPV-16 E5 (pc-16E5, pL2-16E5) were analysed by 
immunoblotting with mAb HC10 (anti-heavy chain, hc), anti-TAP-1 antiserum, or mAb AB-
1 (anti-actin).   
Figure 5. IFN treatment rescues transport of HLA class I to the cell surface. A, Parental 
HaCaT cells (three lines), cells carrying empty vectors (pcDNA and pL2, three lines each) or 
cells expressing HPV-16 E5 (pc-16E5, pL2-1E5, three lines each) were treated with 500U/ml 
β-IFN for 48 h and analysed for expression of total and surface HLA class I by FACS 
analysis with mAb W6/32. The average mean fluorescence for each expression vector was 
calculated from the flow cytometric analyses. A background of 0.4 (the reading of cells 
stained with no primary antibody and only secondary antibody) was subtracted in all cases. 
Standard deviation (+/- ) is shown. B, Immunofluorescence detection of HLA class I with 
MAb W6/32 in at least three cell lines carrying empty vector (pcDNA) or expressing HPV-16 
E5 (pc-16E5), untreated or treated with β-IFN as in A. N, nucleus. Representative lines are 
shown. 
Figure 6. HPV-16 E5 does not down-regulate HLA-C/E. A, FACS analysis of surface and 
total HLA-C/E with mAb DT9 in parental HaCaT cells (three cell lines), cells carrying empty 
vectors (pcDNA and pL2, three lines for each vector) or expressing HPV-16 E5 (three lines 
of pc-16E5 and four of pL2-16E5). The average mean fluorescence for each expression 
vector was calculated from the flow cytometric analyses (example in panel B). A background 
of 0.4 (the reading of cells stained with no primary antibody and only secondary antibody) 
was subtracted in all cases. Standard deviation (+/- ) is shown. B, Representative FACS 
profiles of pc-16E5 and pL2-16E5 cells (one line of each). Dotted line and open histogram: 
forward fluorescence with secondary antibody only; solid histogram: forward fluorescence 
with primary and secondary antibody. C, Immunofluorescence detection of HLA-C/E with 
mAb DT9 in two lines each of cells carrying empty vector (pL2) or expressing HPV-16 E5 
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(pL2-16E5). N, nucleus. D, Detection of HLA-E heavy chain by immunoblotting. Protein 
lysates from three lines each of parental HaCaT cells, cells carrying empty vector (pcDNA3 
or pL2) or expressing E5 (pc-16E5 or pL2-16E5) were analysed by immunoblotting with 
mAb MEM-E/02 (anti-HLA-E) or mAb AB-1 (anti-actin). Representative lines are shown. 
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